A female baby with a severe thrombocytopenia at 18 × 109/l was born to a 29-year-old (gestation 2/partum 2) mother. Scattered petechiae were present on her legs, arms, chest and face, but there was no bleeding, infection, fever or hepatosplenomegaly. A platelet antibody screening immunocapture test was positive, which was performed on the mother’s serum 3, 12 and 38 days after delivery, but no platelet-specific antibodies were found by the monoclonal-antibody-specific immobilization of platelet antigen assay. The baby’s platelets and lymphocytes and the father’s platelets reacted strongly with the HLA antibodies present in the mother’s serum. The neonate was treated with intravenous human immunoglobulin (Tegeline®, 1 g/kg per day) 1, 2 and 3 days after delivery. The platelet count rose from 18 × 109/l on day 0 to 37 × 109/l on day 3 and to 227 × 109/l on day 12. No platelet transfusion was needed. Several factors which developed hereafter lead us to think that this neonatal alloimmune thrombocytopenia is due to the transplacental passage of maternal HLA antibodies to the baby.

Keywords:
Antibody, HLA, Neonate, Thrombocytopenia
1.
Van Loghem JJ, Dorfmeijer H, Van der Hart M, Schreuder F: Serological and genetical studies of a platelet antigen (Zw). Vox Sang 1959;4:161–169.
2.
Van dem Borne AEG, Decary F: Nomenclature of platelet-specific antigens. Hum Immunol 1990;29:1–2.
3.
Panzer S: Report on the Tenth International Platelet Genotyping and Serology Workshop on behalf of the International Society of Blood Transfusion. Vox Sang 2001;80:72–78.
4.
Müeller-Eckhardt C, Kiefel V, Grubert A, Kroll H, Weisheit M, Schmidt S, Müeller-Eckhardt G, Santoso S: 348 cases of suspected neonatal allo-immune trhombocytopenia. Lancet 1989;i:363–366.
5.
Dreyfus M, Kaplan C, Verdy E, Schlegel N, Durand-Zaleski I, Tchernia G and the Immune Thrombocytopenia Working Group: Frequency of immune thrombocytopenia in newborns: A prospective study. Blood 1997;89:4402–4406.
6.
Chow MP, Sun KJ, Yung CH , Hu HY, Tzeng JL, Lee TD: Neonatal allo-immune thrombocytopenia due to HLA-A2 antibody. Acta Haematol 1992;87:153–155.
7.
Sasaki M, Yagihashi A, Kobayashi D, Watanabe N, Fujikawa T, Chiba S, Sato S, Morishita K, Sikimoto T, Ikida H: Neonatal allo-immune thrombocytopenia due to anti-human leucocyte antigen antibody: A case report. Pediatr Hematol Oncol 2001;18:519–524.
8.
Tanaka T, Umesaki N, Nishio J, Maida K, Kawamura T, Araki N, Ogita S: Neonatal thrombocytopenia induced by maternal anti-HLA antibodies: A potential side effect of allogenic leukocyte immunization for unexplained recurrent aborters. J Reprod Immunol 2000;46:51–57.
9.
King KE, Kao KJ, Bray PF, Casella JF, Blakemore K, Callan NA, Kennedy SD, Klickler TS: The role of HLA antibodies in neonatal thrombocytopenia: A prospective study. Tissue Antigens 1996;47:206–211.
10.
Taaning E: HLA antibodies and foetomaternal allo-immune thrombocytopenia: Myth or meaningful? Transfus Med Rev 2000;14:275–280.
11.
Leach MF, AuBuchon JP: Use of enzyme treatment to enhance reactivity of HLA and platelet-specific antibodies in solid-phase RBC adherence assays. Transfusion 2002;42:476–480.
12.
Kiefel V, Santoso S, Weisheit M, Müeller-Eckkhardt C: Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): A new tool for the identification of platelet-reactive antibodies. Blood 1987;70:1722–1726.
13.
Metcalfe P, Waters AH: HPA-1 typing by PCR amplification with sequence-specific primers (PCR-SSP): A rapid and simple technique. Br J Haematol 1993;85:227–229.
14.
Simsek S, Bleeker PMM, Heeremans J, von dem Borne AEG: Human platelet antigen-5 (Br) genotyping by ASPA: Allele-specific primer amplification (PCR-SSP). Br J Haematol 1994;88:659–661.
15.
Metcalfe P, Bleeker PMM, von dem Borne AEG, Ouwehand WH: Human platelet antigen-2 and -3 genotyping by PCR-SSP. Transfus Med 1995;5:285–288.
16.
Klüter H, Fehlau K, Panzer S, Kirchner H, Bein G: Rapid typing for human platelet antigen systems -1, -2, -3 and -5 by PCR amplification with sequence-specific primers. Vox Sang 1996;71:121–125.
17.
Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
18.
Berry JE, Murphy CM, Smith GA, Ranasinghe E, Finberg R, Walton J, Brown J, Navarette C, Metcalf P, Ouwehand WH: Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens. Br J Haematol 2000;110:735–742.
19.
Koyama N, Ohama Y, Kaneko K, Itakura Y, Nakamura T, Takasaki J, Tanaka T, Eguchi H, Kawase A, Kamiya K: Association of neonatal thrombocytopenia and maternal anti-HLA antibodies. Acta Paediatr Jpn 1991;33:71–76.
20.
Husebekk A, Skogen B: Significance of maternal alloantibodies for neonatal thrombocytopenia. Tidsskr Nor Laegeforen 2001;121:3160–3162.
21.
Marshall LR, Brogden FE, Roper TS, Barr AL: Antenatal platelet antibody testing by flow cytometry. Results of a pilot study. Transfusion 1994;34:961–965.
22.
Panzer S, Auerbach L, Cechova E, Fischer G, Holensteiner A, Kittl EM, Mayr WR, Putz M, Wagenbichler P, Walchshofer S: Maternal alloimmunization against fetal platelet antigens: A prospective study. Br J Haematol 1995;90:655–660.
23.
Engelfriet CP, Reesink HW: Prenatal management of alloimmune thrombocytopenia of the fetus. Vox Sang 2003;84:142–149.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.